Reardon, D., Friedman, A., Herndon, J., Quinn, J., Rich, J., Vredenburgh, J., … Friedman, H. (2004). Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. In NEURO-ONCOLOGY (Vol. 6, pp. 381–381). Toronto, CANADA: DUKE UNIV PRESS.

Reardon, D., A. Friedman, J. Herndon, J. Quinn, J. Rich, J. Vredenburgh, M. Badruddoja, et al. “Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma.” In NEURO-ONCOLOGY, 6:381–381. DUKE UNIV PRESS, 2004.

Reardon D, Friedman A, Herndon J, Quinn J, Rich J, Vredenburgh J, et al. Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. In: NEURO-ONCOLOGY. DUKE UNIV PRESS; 2004. p. 381–381.

Reardon, D., et al. “Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma.” NEURO-ONCOLOGY, vol. 6, no. 4, DUKE UNIV PRESS, 2004, pp. 381–381.

Reardon D, Friedman A, Herndon J, Quinn J, Rich J, Vredenburgh J, Badruddoja M, Desjardins A, Sampson J, Gururangan S, Dowell J, Affronti M, Allen D, Jackson S, Zeigler K, Silverman S, Tourt-Uhlig S, Salvado A, Nikolova Z, Bigner D, Friedman H. Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma. NEURO-ONCOLOGY. DUKE UNIV PRESS; 2004. p. 381–381.